January 2, 2026 7:53am

And understanding 2026’s new versus old “rules” of risk and how weighty they are!

Pre-open Signals: 1 Negative and 5 Positive indications. If you understand probabilities, the inevitable is easier to maneuver

Never leave retail investor uninformed … I say what others won’t, so you can do what others can’t

No Don Quixote as I continually ask, what do all these stock sources, I-Banks and brokers do for you in providing daily information? Availability of data have made intel both complex; I see myself as a collector and my responsibility is to further identify and interpret data to bridge some gaps in an investment decision.

 

RegMed Investors (RMi): Happy New Year – 2026

… https://www.regmedinvestors.com/articles/8791   

Wednesday, 12/31 RMi Closing Bell: It’s over

… https://www.regmedinvestors.com/articles/14250

RMi Research Note: Capricor Therapeutics (CAPR) DUMP before the next big SLUMP!

… https://www.regmedinvestors.com/articles/14249

RMi Research Note: Harvard Apparatus GT (OTCQB: HRGN): I reiterate WHO is pumping the volume and share pricing? … https://www.regmedinvestors.com/articles/13812   

 

Friday (1/2): The pre-open Dow futures are UP +0.40% or (+192 points), the S&P futures are UP +0.57% or (+39 points) and the Nasdaq futures are UP +0.95% or (+246 points)

  • U.S. stock futures are on the rise of the 1st trading session of 2026, Friday
  • European markets also extended gains higher
  • Asia Pacific markets are mostly closed (Australia was open yet flat) for the holidays, including Japan and mainland China.

 

Economic Data: US employment report and rates, Hourly wages year-over-year, Un of Michigan sentiment report and US housing starts

 

Henry’omics: We need to more than consider the market’s setting to grasp the micro re “our” universe of cell and gene therapy companies

  • Thursday was New Year’s holiday
  • Wednesday: The Dow closed DOWN -303.77 points or -0.63%, the S&P closed DOWN -50.74 points or -0.74% while the Nasdaq closed DOWN -177.089 points or -0.76%
  • Tuesday: The Dow closed DOWN -94.87 points or -0.20%, the S&P closed DOWN -9.50 points or -0.14% while the Nasdaq closed DOWN -55.27 points or -0.24%
  • Monday: The Dow closed DOWN -249.04 points or -0.51%, the S&P closed DOWN -24.20 points or -0.35% while the Nasdaq closed DOWN -118.748 points or -0.50%
  • Last Friday: The Dow closed DOWN -20.19 points or -0.04%, the S&P closed DOWN -2.11 points or -0.03% while the Nasdaq closed DOWN -20.2 points or -0.09%
  • Last week: The S&P 500 was down -1.2%, the Dow was down -1.3% and the Nasdaq was down -1.5%.
  • The previous week: The S&P 500 was up +1.4%, the Dow +1% and the Nasdaq was also up +0.1%
  • December ended with the S&P 500 up +16.4%, the Dow +13% and the Nasdaq +20.4%

 

Q1/26 – Q1 – 1st session (1/2)

  • Q4 – December, 1 holiday, 8 positive and 12 negative closes
  • November, 1 holiday, 8 positive and 11 negative sessions
  • October, 1 neutral, 10 positive and 12 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Capricor Therapeutics (CAPR) closed down -$0.10 after Tuesday’s -$1.08, Monday’s +$0.35 and Friday’s +$0.01 (having been down -$0.27) after Wednesday’s -$0.57) … with a negative -$0.02) or -0.07% pre-open - SELL

  • I am STICKING to my CONVICTION that CAPR is overbought and whose valuation is disconnected from fundamentals.
  • Doubts still abound re: regulatory fragility and marginal HOPE-3 results and valuation concerns remain a key hang-up!
  • CAPR remains a structurally challenged, chronically unprofitable company whose valuation is disconnected from fundamentals.
  • It has begun; timing will be everything!
  • The higher CAPR rises, the steeper the fall!

Vertex (VRTX) closed down -$0.38 after Tuesday’s-$6.04 after Monday’s -$3.12 with a positive +$0.75 or +0.17% pre-open

IQVIA Holdings (IQV) closed down -$2.28 with a positive +$0.59 or +0.26% pre-open

Moderna (MRNA) closed down -$0.92 with a positive +$0.46 or +1.56% pre-open

Vericel (VCEL) closed down -$0.72 with a positive +$0.13 or +0.36% pre-open

BioLife Solutions (BLFS) closed down -$0.48 with a positive +$0.38 or +1.57% pre-open

 

 

The BOTTOM LINE: Welcome to my world of defining the “grey’ in our universe!

The Santa Claus rally" — during the last five trading days of December and 1st 2 trading sessions of January — has so far sputtered.

Investors are hoping for continued momentum, as they gauge the prospects for a Santa Claus rally.

  • In the week ahead, those investors still around after the New year will forget the “Santa Claus rally

 

Last week of December, Q4 and FY25

  • Wednesday closed negative with 18 positive, 22 negative and 5 flats
  • Tuesday closed negative with 7 positive, 31 negative and 2 flats
  • Monday closed negative with 12 positive, 24 negative and 4 flats

 

As the leading voice of cell and gene therapy investors; I am NOT always a doom and gloom analyst/journalist but a man who has been “there” (BUY, SELL, VC and multiple operating roles) with the gray hair and a readership following with real numbers to prove it!

  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC):

The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.